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Abstract
Background: Hypoxic-ischemic (HI) brain injury remains a major problem in newborns, resulting in increased risk
of neurological disorders. Neonatal HI triggers a broad inflammatory reaction in the brain, including activation of
the innate immune system. Toll-like receptors (TLRs), which are key components of the innate immune system, are
believed to play a role in adult cerebral ischemic injury. The expression of TLRs in the neonatal brain and their
regulation after HI is unknown.
Methods: Wild type C57BL/6, TLR 1 knockout (KO) and TLR 2 KO mice were subjected to HI at postnatal day 9 and
sacrificed 30 min, 6 h, 24 h or 5 days after HI. TLR mRNA expression was determined by RT-qPCR and protein and
cell type localisation by immunohistochemistry (IHC). To evaluate brain injury, infarct volume was measured in the
injured hemisphere.
Results: mRNA expression was detected for all investigated TLRs (TLR1-9), both in normal and HI exposed brains.
After HI, TLR-1 was down-regulated at 30 min and up-regulated at 6 h and 24 h. TLR-2 was up-regulated at 6 h
and 24 h, and TLR-7 at 24 h. Both TLR-5 and TLR-8 were down-regulated at 24 h and 30 min respectively. IHC
showed an increase of TLR-1 in neurons in the ipsilateral hemisphere after HI. TLR-2 was constitutively expressed in
astrocytes and in a population of neurons in the paraventricular nucleus in the hypothalamus. No changes in
expression were detected following HI. Following HI, TLR-2 KO mice, but not TLR-1 KO, showed a decreased infarct
volume compared to wild type (p = 0.0051).
Conclusions: This study demonstrates that TLRs are regulated after HI in the neonatal brain. TLR-1 protein was up-
regulated in injured areas of the brain but TLR-1 KO animals were not protected from HI. In contrast, TLR-2 was
constitutively expressed in the brain and TLR-2 deficiency reduced HI injury. These data suggest that TLR-2, but not
TLR-1, plays a role in neonatal HI brain injury.
Background
Perinatal brain injury remains a major clinically acute
and chronic problem resulting in increased risk of neu-
rological disorders such as cerebral palsy and epilepsy.
Although the precise aetiology of brain injury in the
newborn is sometimes unclear, hypoxia-ischemia (HI) is
well accepted as a contributing factor [1]. Both infection
and intrapartum asphyxia is associated with inflamma-
tion in the brain [2] and there are increased levels of
cytokines in the cerebral spinal fluid in term infants that
have suffered birth asphyxia [3]. Experimental studies
demonstrate that neonatal HI triggers a broad
inflammatory reaction in the brain which includes acti-
vation of the innate immune system [4] and several stu-
dies in neonatal animals have shown that inhibition of
pro-inflammatory mediators are neuroprotective [5-8].
Toll-like receptors (TLRs) are key components of the
innate immune system, which recognise a wide variety
of pathogen-associated molecular patterns (PAMPs),
such as lipopolysaccharide, bacterial DNA, and double-
stranded RNA (for reviews see [9-11]). The TLR family
consists of 13 members and TLR 1-9 are expressed in
both mice and humans. Upon activation, each toll-like
receptor, except TLR-3, signals through the myeloid dif-
ferentiation primary response gene 88 (MyD88)-depen-
dent pathway. MyD88 is an adaptor protein, which
upon recruitment to the activated receptor initiates a
signalling cascade leading to activation of different
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activator protein-1 (AP1). This activation then gives rise
to a generation of pro-inflammatory cytokines such as
interleukin (IL)-6 and tumour necrosis factor-a (TNF-
a). In contrast, TLR-3 signals through the MyD88-inde-
pendent pathway, initiated by the Toll/IL-1R domain
containing adaptor inducing IFN-b (TRIF) molecule.
Recruitment of TRIF leads to the activation of the tran-
scription factor interferon regulatory factor (IRF) -3 and
-7 and the generation of antiviral molecules such as
interferon (IFN)-b.
In addition to their role in bacterial and viral infections,
recent studies have shown that TLRs also recognise and
are activated by endogenous molecules associated with
damaged cells and tissues [12-14]. For example, Lehnardt
et al. demonstrated that the intracellular chaperone heat
shock protein 60 released from dying cells in the central
nervous system activates microglia through a TLR-4- and
MyD88-dependent pathway [13]. In addition, Karikó et
al. revealed that RNA released from or associated with
necrotic cells stimulated TLR-3 and induced an immune
response [12]. Furthermore, growing evidence suggests
that TLRs play a role in ischemic brain damage. In adult
studies, TLR-4 has been found to be up-regulated after
cerebral ischemia reperfusion [15] and mice lacking
TLR-2 or TLR-4 are less susceptible to hypoxic/ischemic
brain damage [16-19].
Most TLRs are constitutively expressed in the adult
brain [20,21]. However, the expression of TLRs in the
neonatal brain and how they are regulated after HI is
unknown. Here we examine the expression of TLR 1-9
in the neonatal brain, both in control animals and after
HI using a well-established animal model of perinatal
brain damage [6,22]. Furthermore, we examined the
functional role of TLR-1 and TLR-2 after HI.
Methods
Animals
C57BL/6 mice were purchased from Charles River (Sulz-
feld, Germany). TLR-1 knock out (KO) mice were pur-
chased from Oriental BioService, Inc (Tokyo, Japan) and
TLR-2 KO mice (B6.129-Tlr2tm1Kir/J) were bought
from the Jackson Laboratory (USA). All KO mice were
on the C57BL/6 background. Mice were housed in a 12
h light-dark cycle and bred at Experimental Biomedicine
(Gothenburg University, Gothenburg, Sweden) and were
provided with a standard laboratory chow diet (B&K,
Solna, Sweden) and drinking water ad libitum.A l la n i -
mal experiments were approved by the Ethical Commit-
tee of Gothenburg (No.277-07 and 374-09).
Induction of hypoxia-ischemia in neonatal mice
At postnatal day (PND) 9, mice were anesthetised with
isoflurane (3.0% for induction and 1.0-1.5% for
maintenance) in a mixture of nitrous oxide and oxygen
(1:1). The left common carotid artery was ligated with
prolene sutures (the whole procedure was less than
5 min). Mice were returned to the cage and allowed to
recover for 1 h and then placed in an incubator circu-
lated with a humidified gas mixture (10.00 ± 0.01% oxy-
gen in nitrogen) at 36°C for 50 min. After hypoxia, the
pups were returned to their dam until sacrifice. Control
animals received no surgery and were not subjected to
HI. Two wild type and one TLR-1 KO mice died during
the HI procedure.
Tissue collection and processing
For mRNA expression analysis, wild type pups were
deeply anesthetized and intracardially perfused with sal-
ine at 30 min (n = 5), 6 h (n = 5) and 24 h (n = 5)
after HI. Brains were rapidly dissected out, divided into
ipsi- and contralateral hemispheres, snap frozen and
then stored at -80°C until analysis. Brain tissue was
homogenised with Qiasol lysis reagent homogeniser
(Qiagen, Solna, Sweden) and total RNA was extracted
using RNeasy Lipid Tissue Mini Kit (Qiagen, Solna,
Sweden) according to the manufacturer’si n s t r u c t i o n s .
RNA was measured in a spectrophotometer at 260-nm
absorbance.
For immunohistochemical analysis, animals were dee-
ply anesthetised and intracardially perfused with saline
and 5% buffered formaldehyde (Histofix; Histolab, Swe-
den) at 30 min, 6 h, 24 h and 5 days after HI. Brains
were rapidly removed and immersion fixed in 5% for-
maldehyde for 24 h. Brains were then kept in a 30%
sucrose solution until they were cut or put through
dehydration with graded ethanol and xylene and
embedded in paraffin. Coronal sectioning (25 μm/sec-
tion) was performed on a sliding microtome (Leica
SM2000R, Leica Microsystems, Sweden), and sections
were stored in tissue cryoprotectant solution (25% ethy-
lene glycol, 25% glycerol and 0.1 M phosphate buffer) at
-20°C. For detection of infarction volume paraffin
embedded tissue was used. Paraffin embedded brains
were cut coronally (10 μm/section) on a rotating micro-
tome (Leica RM2165, Leica Microsystems, Sweden).
TLR signalling pathway RT2-PCR-Profiler PCR Array
cDNA-synthesis was performed by using the RT
2 First
Strand Kit (SABiosciences, Frederick, MD, USA) follow-
ing the manufacturer’s instructions. The mouse TLR
signalling pathway RT
2-PCR-Profiler PCR Array
(SABiosciences, Frederick, MD, USA) was carried out
according to manufacturer’s instructions using the
LightCycler 480 system (Roche, Bromma, Sweden). The
raw data obtained from the Lightcycler 480 software
was uploaded into GEarray Analyzer software (SABios-
ciences, Frederick, MD, USA) for analysis.
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To confirm the RT
2-PCR-Profiler PCR Array results,
TLR-1 and -2 mRNA expressions were determined by
reverse transcription-quantitative PCR (RT-qPCR).
Superscript RNase H- reverse transcriptase kit (Invitro-
gen, CA, USA) random hexamer primers and dNTP
(Roche Molecular Biochemicals, IN, USA) were used to
synthesise first strand cDNA as previously described
[23]. Each PCR (20 μl) contained 2 μl cDNA diluted 1:8,
10 μl Quanti Fast SYBR Green PCR Master Mix (Qia-
gen, Sweden) and 2 μl PCR primer. The following pri-
mers were used: TLR-1 QuantiTech Primer Assay
(QT00157430), TLR-2 QuantiTech Primer Assay
(QT00129752) and Hprt-1 QuantiTech Primer Assay
(QT00166768), all from Qiagen, Sweden. The amplifica-
tion protocol comprised an initial 5 min denaturation at
95°C, followed by 40 cycles of denaturation for 10 sec at
95°C and annealing/extension for 30 sec at 60°C on a
LightCycler 480 (Roche, Sweden). Melting curve analysis
was performed to ensure that only one PCR product
was obtained. For quantification and for estimation
amplification efficiency, a standard curve was generated
using increasing concentrations of cDNA. The amplifi-
cation transcripts were quantified with the relative stan-




Immunohistochemical staining was performed on free-
floating 25 μm sections pretreated with 0.6% H2O2 in
Tris-buffered saline (TBS; 0.15 M NaCl and 0.1 M Tris-
HCl, pH 7.5) for 30 min to block endogenous peroxi-
dase activity. Nonspecific binding was blocked for 30
min in blocking solution (3% goat serum and 0.1% Tri-
ton-X 100 in TBS). After rinsing, sections were incu-
bated with primary antibody (TLR-1, IMG-5012, 1:500,
TLR-2, IMG-526, 1:100, Imgenex, CA, USA) in blocking
solution at 4°C for 48 h. The tissue sections were then
incubated for 1 h with biotinylated goat anti-rabbit IgG
secondary antibody (1:500, Vector Laboratories, CA,
USA) in blocking solution and then rinsed in TBS.
Visualisation was performed using Vectastain ABC Elite
(Vector Laboratories, CA, USA) with 0.5 mg/ml 3, 3’-
diaminobenzidine (DAB) enhanced with 0,01% H2O2
and 0,04% NiCl (all from Sigma-Aldrich, Sweden). Sec-
t i o n sw e r ea n a l y s e do na nO l y m p u sB X 6 0f l u o r e s c e n c e
microscope equipped with an Olympus DP50 cooled
digital camera.
For paraffin sections, antigen recovery was performed
by boiling the sections in 10 mM sodium citrate buffer
(pH 6.0) for 10 min. Nonspecific binding was blocked
for 30 min in blocking solution (1% horse serum, 3%
bovine serum albumin, 0.1% NaN3 in phosphate
buffered saline (PBS)). Sections were incubated in pri-
mary antibody against microtubule-associated protein-2
(MAP-2; clone HM-2, 1:1000; Sigma-Aldrich) at 4°C
overnight, followed by biotinylated horse anti-mouse
secondary anti body (1:250, Vector Laboratories) for
60 min at room temperature. Visualization was per-
formed using Vectastain ABC Elite with 0.5 mg/ml 3,3--
diaminobenzidine enhanced with 15 mg/ml ammonium
nickel sulfate, 2 mg/ml b-D-glucose, 0.4 mg/ml ammo-
nium chloride, and 0.01 mg/ml b-glucose oxidase (all
from Sigma-Aldrich).
To identify the cell type specific localisation of TLRs,
multi-immunofluorescence staining was performed.
Non-specific binding was blocked for 30 min in block-
ing solution (3% donkey serum and 0.1% Triton-X 100
in TBS). TLR antibodies were then incubated simulta-
neously with antibodies against specific markers for neu-
rons (NeuN 1:1000, MAB377, or alexa 488 conjugated
NeuN 1:1000, MAB377X, Chemicon International, USA,
and HuC/D 1:500, A21271, Molecular Probes, Nether-
lands), oligodendrocytes (Olig2 1:1000, AF2418, R&D
systems, UK), microglia (Iba-1 1:1000, ab5076, Abcam,
UK), and astrocytes (GFAP 1:1000, PCK-591P, Covance,
USA) diluted in blocking solution for 48 h at 4°C. Sam-
ples stained for HuC/D were subjected to sodium citrate
antigen retrieval (10 mM NaCi, pH6 for 30 min at 80°C)
prior to blocking. Immunoreactivity was visualised via
appropriate combinations of the following secondary
antibodies: donkey anti-chicken DyLight 549 (1:1000,
Jackson ImmunoResearch, USA), donkey anti-mouse
Alexa 488, donkey anti rabbit Alexa 594, donkey anti-
goat Alexa 647, and donkey anti-rabbit Alexa 488
(1:1000, all from Molecular probes, Netherlands). Multi-
channel confocal images were captured with a Leica
TCS SP2 confocal system (Leica, Heidelberg, Germany)
with channel settings appropriate to the fluorophores
present. Sequentially scanned, grey scale Z-stacks were
pseudocolored and processed in ImageJ (version 1.42u;
National Institutes of Health, Bethesda, MD, http://rsb.
info.nih.gov/ij) before final processing in Adobe Photo-
shop (version 11.0.2; Adobe Systems Inc., San Jose, CA).
Brain infarct evaluation
For brain infarct evaluation, coronal paraffin sections
throughout the hippocampus were used. Every 40th sec-
tion was stained for MAP-2 and analyzed under a
Nikon Optiphot-2 microscope equipped with an Olym-
pus DP50 cooled digital camera. Images were captured
a n dp r o c e s s e du s i n gM i c r oI m a g ev e r s i o n4 . 0( O l y m -
pus). Infarct area was assessed as the MAP-2 negative
area in the ipsilateral hemisphere and total infarct
volume was calculated according to the Cavalieri Princi-
ple using the following formula: V = ∑A × P × T, where
V = total volume, ∑A = the sum of areas measured, P =
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the section thickness.
Data analysis and Statistics
For normalisation of gene expression on the RT
2-PCR-
Profiler PCR Array, five housekeeping genes, b-glucuroni-
dase, Hprt-1, heat shock protein 90 kDa alpha, glyceralde-
hyde-3-phosphate dehydrogenase, and b-actin, were used.
The cycle threshold (CT) was determined for each sample
and normalised to the average CT of the five housekeeping
genes. A comparative CT method was used to calculate
relative gene expression. Data are represented as fold
change relative to control. The p-value was calculated
using a student’s t-test (two-tailed, equal variance).
Brain infarct data were analyzed with one way
ANOVA followed by Dunnett’s Multiple Comparison
Test to compare total infarct volume between genotypes
or infarct area at each brain level between groups (WT,
TLR-1 KO and TLR-2 KO). Data are presented as mean
± SD and significance was set at p ≤ 0.05. All statistical
analyses were performed using GraphPad Prism 4.0
(GraphPad Software).
Results
mRNA expression of TLRs in normal brain and after
hypoxia-ischemia
mRNA expression was detected for all TLRs present on
t h ea r r a yi nt h eP N D9m o u s eb r a i n( T a b l e1 ) .F o l l o w -
ing HI, TLR-1 mRNA was down-regulated at 30 min
(fold change 0.52, p = 0.004) then up-regulated at 6 h
(fold change 2.39, p = 0.00001) and 24 h (fold change
3.36, p = 0.00001); TLR-2 was up-regulated at 6 h (fold
change 1.63, p = 0.005) and 24 h (fold change 2.27, p =
0.006) and TLR-7 was up-regulated at 24 h (fold change
2.16, p = 0.005). Solely down regulated gene expression
after HI was found with TLR-5 at 24 h (fold change
0.57, p = 0.004) and TLR-8 at 30 min (fold change 0.39,
p = 0.006). TLR-3, -4, -6 and -9 mRNA expression did
not show any significant changes after HI.
To confirm the RT2-PCR-Profiler PCR Array results,
mRNA expression levels for TLR1 and TLR2 were
examined using RT-qPCR and normalised against the
reference gene Hprt-1. TLR-1 and -2 were selected as
they showed both mRNA up-and down-regulation on
the array. A similar pattern of mRNA expression was
observed for both TLR-1 and -2, when comparing the
methods (Figure 1). On the array, TLR-1 showed a fold
change of 0.52 at 30 min and 3.36 at 24 h after HI.
When using RT-qPCR and the TLR-1 expression nor-
malised against Hprt-1 the fold change was 0.02 at
30 min and 4.61 at 24 h (Figure 1A). For TLR-2, the
array showed a fold change of 1.23 at 30 min and 2.27
at 24 h after HI. RT-qPCR for TLR-2 gave a fold change
Table 1 Fold change values for TLRs 30 min, 6 h and 24
h after HI
Fold change (p-value)
30 min 6 h 24 h
TLR 1 0.52 (0.004) 2.39 (0.00001) 3.36 (0.00001)
TLR 2 1.23 (n.s) 1.63 (0.005) 2.27 (0.006)
TLR 3 0.59 (n.s) 0.83 (n.s) 1.00 (n.s)
TLR 4 0.95 (n.s) 1.20 (n.s) 0.95 (n.s)
TLR 5 0.64 (n.s) 0.88 (n.s) 0.57 (0.004)
TLR 6 0.68 (n.s) 1.35 (n.s) 1.28 (n.s)
TLR 7 0.91 (n.s) 1.23 (n.s) 2.16 (0.005)
TLR 8 0.39 (0.006) 1.68 (n.s) 1.17 (n.s)
TLR 9 1.04 (n.s) 0.92 (n.s) 0.76 (n.s)
Figure 1 Comparison of gene expression for TLR-1 and TLR-2
using TLR array and RT-qPCR. Gene expression for TLR-1 (A) and
TLR-2 (B) was confirmed with RT-qPCR (black bars) at 30 min and
24 h after HI and compared with TLR signalling pathway RT2-PCR-
Profiler PCR Array (grey bars). RT-qPCR expression for TLR-1 and TLR-
2 was calculated using Hprt-1 as housekeeping gene. Controls were
not subjected to HI. n = 5 for 30 min, 24 h time points and
controls.
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malised against Hprt-1 (Figure 1B).
Protein expression and distribution of TLR-1 and -2 in the
brain after hypoxia-ischemia
To further study TLR regulation following injury, we
performed immunohistochemical studies of the TLRs
that displayed significant up-regulation of mRNA in
response to HI, i.e. for TLR1 and 2. Immunohistochem-
ical experiments performed using an antibody against
TLR -7 were unsatisfactory and were not analysed
further (data not shown).
No TLR-1 staining was detected in normal control
brains or in the contralateral (non-damaged) hemisphere
following HI. There was a marked increase of TLR-1
positive cells in the ipsilateral (damaged) hemisphere at
24 h, but not 30 min and 6 h after HI. TLR-1 positive
staining was mainly observed in the hippocampus (Fig-
ure 2A) Double/triple-labelling experiments showed that
TLR-1 was expressed in neurons (Figure 3A and 3C)
but not in microglia, astrocytes or oligodendrocytes
(Figure 3A and 3B).
TLR-2-immunoreactivity was observed mainly in the
hippocampus, subcortical white matter and stria termi-
nalis (Figure 2B and 2C). Co-staining experiments con-
firmed that TLR-2 positive cells in white matter areas
were astrocytes but not neurons, microglia or oligo-
dendrocytes (Figure 4A-C). A specific population of
neuron-like cells expressing TLR-2 was found in the
paraventricular nucleus of the hypothalamus (PVN,
Figure 2B and 2D) and was confirmed to be neurons
by co-staining experiments (Figure 4D). The immuno-
histochemical expression of TLR-2 did not change
after HI.
Brain infarct in wild type, TLR-1 and -2 KO animals after
hypoxia-ischemia
To further evaluate the role of TLR-1 and TLR-2 in the
neonatal brain after HI, we performed studies with
TLR-1 and TLR-2 KO mice. Neuropathological analysis
at 5 days after HI showed a significant decrease in
infarct volume in TLR-2 KO mice (1.162 ± 0.791 mm
3,
p = 0.005, n = 15) compared to WT (2.528 ± 1.570
mm
3, n = 14, Figure 5A). There was no protection in
TLR-1 KO mice (2.068 ± 0.607 mm
3,n=1 3 ) .T h e
infarct area was significantly decreased in 3 out of 4
levels throughout hippocampus in TLR-2 KO mice com-
pared to WT (Figure 5B). Figure 5C demonstrates repre-
sentative images of level 3 of the hippocampus for the
different genotypes.
Discussion
We detected mRNA transcripts for all TLRs (TLR1-9) in
the normal immature brain and regulation of mRNA
expression for TLR-1, -2, -5, -7 and -8 after HI, with the
largest up-regulation occurring for TLR-1 and TLR-2.
Both TLR-1 and -2 immunoreactivity was also detected
in the brain, however, only TLR-2 KO mice were pro-
tected from HI injury suggesting that TLR-2 may play
an important role in neonatal HI.
Figure 2 TLR-1 and TLR-2 immunostaining 24 h after hypoxia-
ischemia. A: Representative picture of TLR-1 immunostaining 24 h
after hypoxia-ischemia (HI). TLR-1 positive cells were found in the
ipsilateral (damaged) side of the brain, primarily in hippocampus,
striatum and thalamus. B: Representative picture of TLR-2
immunostaining 24 h after HI. TLR-2 positive cells were found in
white matter e.g. stria terminalis and in the paraventricular nucleus
of hypothalamus (PVN). C: High magnification of TLR-2 positive cells
in stria terminalis representing the area of the C box in figure B. D:
High magnification of TLR-2 positive cells in the PVN representing
the area of the D box in figure B. Scale bars: A-B: 500 μm, C-D: 50
μm.
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TLR 1-9 mRNA in the normal neonatal brain under
physiological conditions. Similarly, studies in human
cerebral tissue have indicated that mRNA for most
TLRs is expressed in numerous cell types [20]. In vitro
studies also indicate a broad expression of TLR mRNA
in numerous neural cell types [21,24-26], although the
expression of neuronal TLR mRNA is more controver-
sial [27]. Taken together, TLRs are expressed under
basal conditions in both the immature and adult brain
in numerous cell types and this may again suggest that
they play essential roles in neurophysiology and
pathology.
We showed that the mRNA expression for TLR-1, -2,
-5, -7, and -8 was regulated after HI as shown on PCR
array and confirmed by RT PCR. The regulation of TLR
genes after neonatal HI is consistent with several studies
in the adult brain. After 1 h of middle cerebral artery
occlusion (MCAO), Lehnardt et al. found up-regulation
of TLR-2 mRNA expression and Ziegler et al. found an
induction of TLR-2, -4, and -9 mRNA after focal ische-
mia in mice [17,18]. Also, in a model of spinal cord
injury, there was an increased mRNA expression of
TLR-1, -2, -4, -5, and -7 [28]. This is to some extent
similar to our results indicating an increase of TLR-1,
-2, and -7 after HI. However, in contrast to studies in
adult rodents, we found reduced mRNA expression of
TLR-5 (24 h after HI) and TLR-8 (30 min after HI).
TLR-3, -4, -6 and -9 were not significantly changed after
neonatal HI, which suggests that the TLR response to
cerebral ischemia differs in the adult compared to the
developing brain.
We further investigated the protein distribution of the
most regulated TLR genes following HI by immunohis-
tochemical analysis. We found an increase of TLR-1,
immunoreactivity in the ipsilateral hemisphere after HI,
Figure 3 Neurons express TLR-1 24 h after hypoxia-ischemia. A: Triple immunofluorescence staining for TLR-1, NeuN and Iba-1; the merged
picture displays expression of TLR-1 by NeuN positive neurons but not Iba-1 positive microglia. B: Triple immunofluorescence staining for TLR-1,
GFAP and Olig2; The merged picture shows mutually exclusive expression of TLR-1, GFAP Olig2 and no co-localisation of all three markers. C:
High magnification orthogonal views of cells stained with TLR-1 and NeuN; the merged picture shows membranous localisation of TLR-1
surrounding NeuN positive nuclei. All images were captured in the ipsilateral hippocampus. Scale bars: A-B: 25 μmC :1 0μm
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tal brain and the expression did not change with HI.
Thus, the pattern of protein expression after HI differed
to some extent to the mRNA expression. Similarly, Mis-
hra et al. have found differences between mRNA and
protein expression and speculate that TLRs can be post-
transcriptionally regulated [21].
In the HI model used in this study, brain injury is pre-
dominantly found in the hippocampus, striatum and
thalamus [7]. Interestingly, TLR-1 showed increased
Figure 4 TLR-2 is expressed in astrocytes and neurons. A: Triple immunofluorescence staining for TLR-2, Iba-1 and HuC/D; the merged
image indicates mutually exclusive expression of TLR-2, Iba-1 and HuC/D positive cells in the ipsilateral hippocampus. B: Triple
immunofluorescence staining for TLR-2, GFAP and Olig2; the merged picture displays apparent co-expression of TLR-2 and GFAP. C: High
magnification XYZ, XZ, YZ-average projections of TLR-2 and GFAP co-expressing cells; TLR-2 appears to be associated with cytoskeletal protein
GFAP in astrocytes. Pictures A-C were captured in the ipsilateral hippocampus. D: High magnification orthogonal views of TLR-2 and HuC/D
double stains in cells in the paraventricular nucleus of the hypothalamus (PVN); the merged picture shows punctate, membranous expression of
TLR-2 on HuC/D positive neurons of the PVN. Scale bars: A-B: 25 μm C-D: 10 μm
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these brain regions. To our knowledge, there are no pre-
vious studies of TLR-1 expression after ischemic injury,
either in the adult or developing brain. However, after
induction of neurocysticercosis in adult mice, TLR-1
staining was found almost exclusively in infiltrating cells
such as microglia/macrophages [21]. These differences
in expression may be due to age-and/or injury- depen-
dent factors. Other TLRs have been suggested to have
adverse effects on brain development. Deficiency of
TLR-3, which is predominantly expressed during
embryonic life, increases proliferation of neural progeni-
tor cells [29]. Ma et al. have shown that TLR-8 is
expressed on neurons and axons during mouse brain
development and that stimulation of this receptor leads
to inhibition of neurite outgrowth and induction of
apoptosis [30]. Taken together, these studies give sup-
port to the hypothesis that activation of certain TLRs
can be harmful to the developing brain; however, based
on the findings in the present study, the increased
expression of TLR-1 in the ischemic brain does not
appear to contribute to neonatal damage. In support, we
have previously shown that mice deficient in the TLR-1
down-stream adaptor protein MyD88 are not protected
from neonatal HI injury [31].
The immunohistochemical expression pattern of TLR-
2 was different to that of TLR-1, with a constitutive
expression both in white matter astrocytes and in a spe-
cific population of neurons in PVN. TLR-2 expression
has previously been detected in microglia, neurons,
ependymal cells and astrocytes, [21] and constitutive
expression of TLR-2 has been demonstrated by in situ
hybridisation specifically in stria terminalis, PVN, and in
the supraoptic nucleus [32]. Thus, our results corre-
spond well with previous reports. Existing studies have
shown both a neuroprotective [33] and a damaging
[17,18,26,34] role for TLR-2 in the injured brain. It has
also been demonstrated that cerebral cortical neurons
Figure 5 Neuroprotection in TLR-2 KO mice after HI. Neuropathological analysis at 5 days after HI showed a significant decrease in infarct
volume (A) in TLR-2 KO mice (1.162 ± 0.791 mm
3, n = 15) compared to WT (2.528 ± 1.570 mm
3, n = 14, p = 0.0051). There was no protection
in TLR-1 KO mice (2.068 ± 0.607 mm
3, n = 13). The infarct area (B) was significantly attenuated in 3 out of 4 levels throughout hippocampus in
TLR-2 KO mice compared to WT. C: Representative images of level 3 of the hippocampus for the different genotypes. Data is shown as mean ±
SD. *≤ 0.05, **≤ 0.01. C: Scale bar: 1 mm.
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injury and that an increased number of apoptotic neu-
r o n sa r ef o u n di nt h em u r i n ed e n t a t eg y r u s2 4ha f t e r
stimulation with a TLR-2 agonist [26,34]. Other studies
have found that TLR-2 is involved in adult hippocampal
neurogenesis [35] and that after a spinal cord injury,
TLR-2 is important for the regulation of inflammation
and gliosis as well as the repair and functional recovery
[28]. We have recently found that repeated stimulation
of the TLR-2 receptor during early neonatal develop-
ment by administration of the TLR-2 agonist
Pam3CSK4 results in brain injury and this effect is
blocked in TLR-2 deficient mice [36]. Thus these data
in neonatal animals support the findings in the present
study where TLR-2 KO animals demonstrated a
decrease in infarct volume following HI. These results
may seem contradictory to our previous results showing
no neuroprotective effect in the TLR-2 adaptor protein
MyD88. However, studies in adult animals have also
shown a differential effect of MyD88 KO and TLR-2 KO
following brain damage [37].
We found a specific population of TLR-2 positive neu-
rons in the PVN. Inflammatory stimuli, such as LPS, are
known to activate secretory neurons in PVN, a neuronal
subpopulation that is important for homeostatic control
[38]. Specifically, TLR-4 and MyD88 have been implicated
in circadian responses and anorexia respectively [39,40].
The function of the TLR-2 immunoreactive neurons in
PVN is unknown but we speculate that they may partici-
pate in the neuroendocrine response of the hypothalamus
and may act as sensors for incoming inflammatory signals.
Conclusions
This study demonstrates that a number of TLRs are regu-
lated after HI in the neonatal brain, both on the mRNA
and protein level. TLR-1 protein expression was found to
be up-regulated in damaged areas of the brain, however
based on the studies in TLR-1 deficient mice, did not
appear to be involved in the injurious processes causing
ischemic injury. In contrast, TLR-2 protein expression was
constitutively expressed and did not change after HI. On
the other hand TLR-2 deficiency did protect the immature
brain from HI damage, which may indicate that TLR-2
plays a role in neonatal ischemic injury.
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